ANI Pharmaceuticals Raises 2026 Guidance on Strong Rare Disease Growth
Event summary
- ANI Pharmaceuticals reported Q1 2026 revenue of $237.5M, up 20.5% YoY, with Cortrophin Gel revenues growing 42.1% YoY to $75.1M.
- The company raised its 2026 revenue guidance to $1.08B–$1.14B, with Rare Disease expected to represent 60% of total revenue.
- ANI authorized a $100M share repurchase program, effective May 8, 2026.
- ILUVIEN revenues increased 19.5% YoY to $19.3M, supported by commercial and patient access initiatives.
- Generics revenue grew 6.8% YoY to $105.4M, driven by new product launches.
The big picture
ANI Pharmaceuticals' strong Q1 2026 performance underscores the strategic importance of its Rare Disease portfolio, particularly Cortrophin Gel, which now represents a growing share of total revenue. The company's ability to raise guidance reflects confidence in its commercial expansion and pipeline, though execution risks remain in scaling new indications and maintaining generics momentum. The $100M share repurchase program signals management's optimism in delivering long-term shareholder value.
What we're watching
- Commercial Execution
- The pace at which ANI's expanded commercial team drives adoption of Cortrophin Gel in acute gouty arthritis flares.
- Rare Disease Growth
- Whether ANI can sustain the 55–65% YoY growth in Cortrophin Gel revenue as it expands into new indications.
- Generics Pipeline
- How the cadence of 10–15 new generics product launches in 2026 impacts revenue diversification.
Related topics